Vertex Pharmaceuticals Incorporated News
Biotech Can't Conquer the Lungs. Will These Stocks Succeed?
The lungs have evolved to keep things out. Can these biotech stocks get drugs in?
5 Biotechs with $1 Billion in Cash
Worried about a recession? These cashed-up biotech stocks aren't sweating it.
bluebird bio (Finally) Nears Approval. What's Next?
The gene therapy pioneer may earn approval years after initially teasing investors. It may not be time to celebrate.
Best Buy, Tyson Make Goldman List of Margin of Safety Stocks
The stocks could thrive amid the current uncertainty in the equity market and the economy, Goldman says.
Cathie Wood Watch: Ark Buys a Sagging Healthcare Stock
Ark did more selling than buying on April 29, including sale of a South African financial services company's stock.
Cathie Wood Watch: This Firm Programs Cells, Using DNA as Code
Wood's Ark Investment Management bought a series of biotech stocks, as it has done repeatedly in recent sessions.
Vertex Has a Pain Pill That May Replace Opioids
Vertex is one step closer to getting its new pain pill approved, which could substitute for opioids that are highly addictive.
Cathie Wood Buys Crypto, Workflow, Navigation-Tech Companies
Cathie Wood's Ark Investment Management noted that privately held tech stocks are now falling just like publicly held ones.
Last Week Provided Good News for Cathie Wood, Ark
Ark's flagship Ark Innovation ETF has dropped 31% this year, but it has outperformed the S&P 500 over the last five years.
Breaking News
Johnson & Johnson Stock Lower After Unveiling End To Global Baby Powder Sales In 2023
Johnson & Johnson, which began selling Baby Powder in 1894, will end all sales of the talc-based product next year.
Apple Stock Edges Higher After Report Indicates iPhone Demand Confidence
Apple is asking assemblers to put together 220 million iPhones this year, Bloomberg reported, a tally that largely matches 2021 levels.
Struggling Electric-Truck Maker Nikola Makes a Major Change
Electric-truck manufacturer Nikola, like the broad vehicle industry, has been struggling with supply-chain issues.
Illumina and the Quest for the (Holy?) Grail
DNA-sequencing leader Illumina swung to a loss in Q2 2022. Contributions from Grail didn't help.